Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States

Applied Health Economics and Health Policy

Volumn 12, Issue 1, 2014, Pages 85-93

  Yang, Hongbo ^a   Chaudhari, Paresh ^b   Zhou, Zheng Yi ^a   Wu, Eric Q ^a   Patel, Chad ^b,d   Horn, David L ^c  

^a ANALYSIS GROUP   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c David Horn LLC   (United States)

^d Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ANAPHYLAXIS; ARTICLE; ASPERGILLOSIS; BUDGET; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG COST; HOSPITAL COST; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFUSION RELATED REACTION; NEPHROTOXICITY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMIC MYCOSIS; TREATMENT DURATION; UNITED STATES;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; COSTS AND COST ANALYSIS; CRYPTOCOCCUS; DRUG COSTS; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; MODELS, BIOLOGICAL; MYCOSES; UNITED STATES;

EID: 84893534198     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0072-7     Document Type: Article

References (25)

1. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66(19):1711-7.
2. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27(4):781-8.
3. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(Pt 7):809-18.
4. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293-300.
5. Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents. 2001;17(3):161-9.
6. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711-8.
7. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(1):205-12.
8. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol. 2004;72(5):342-7.
9. Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol. 1998;103(1):198-204.
10. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155-63.
11. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40(5-6):511-20.
12. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100(3):581-9.
13. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112(6):1282-7.
14. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236-44.
15. Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis. 2013;76(3):361-7.
16. Bureau of Labor Statistics. Consumer price index - all urban consumers. http://www.bls.gov/cpi/. Cited 24 Jan 2012.
17. CMS Medicare Part B Drug Average Sales Price. https://www.cms.gov/ McrPartBDrugAvgSalesPrice/01a17-2012ASPFiles.asp. Cited 24 Jan 2012.
18. Greenberg RN, Cagnoni PJ, Wingard JR, Prendergast MM, Tong KB. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J Med Econ. 2002;5(1-4):109-18.
19. HCUPnet: a tool for identifying, tracking, and analyzing national hospital statistics. http://hcupnet.ahrq.gov/HCUPnet.jsp. Cited 24 Jan 2012.
20. Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Waal JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008;24(6):1743-53.
21. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000;18(12):2476-83.
22. Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532-9.
23. Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics. 2004;22(5):301-10.
24. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26-34.
25. Schneider P, Klein RM, Dietze L, Söhngen D, Leschke M, Heyll A. Anaphylactic reaction to liposomal amphotericin (AmBisome). Br J Haematol. 1998;102(4):1108-9.